Biosimilars equivalence data is lacking, especially for switching: international expert

Rheumatologists are right to be sceptical of claims that biosimilars are equivalent to bio-originator molecules because the evidence is either lacking or flawed, the ARA conference in Melbourne heard. Professor Roy Fleischmann, a Texas-based rheumatologist who has been lead investigator in many clinical trials of biologics, said there was some evidence to show biosimilars may ...

Already a member?

Login to keep reading.

© 2021 the limbic